WG
RCUS icon

Winton Group’s Arcus Biosciences RCUS Stock Holding History

Winton Group’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.62M Buy
52,398
+19,578
+60% +$484K 0.05% 360
2026
Q1 		$709K Sell
32,820
-29,431
-47% -$636K 0.02% 621
2025
Q4 		$1.48M Sell
62,251
-29,978
-33% -$612K 0.05% 342
2025
Q3 		$1.25M Buy
+92,229
New +$959K 0.05% 369
2025
Q2 		– Sell
-115,595
Closed -$907K – 976
2025
Q1 		$907K Buy
115,595
+43,285
+60% +$502K 0.06% 443
2024
Q4 		$1.08M Buy
72,310
+3,730
+5% +$60.9K 0.07% 297
2024
Q3 		$1.05M Buy
68,580
+9,443
+16% +$149K 0.07% 297
2024
Q2 		$901K Buy
59,137
+1,872
+3% +$30.2K 0.06% 321
2024
Q1 		$1.08M Buy
+57,265
New +$990K 0.08% 225
2022
Q1 		– Sell
-6,910
Closed -$280K – 1116
2021
Q4 		$280K Buy
+6,910
New +$268K 0.02% 855

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Winton Group's RCUS Position: Q2 2026 in Review

Winton Group increased its Arcus Biosciences (RCUS) stake by 60% in Q2 2026, buying an estimated $484K and bringing the position to 52,398 shares worth $1.62M. The position accounts for 0.05% of the portfolio, ranked #360.

Winton Group first reported a position in RCUS in Q4 2021 and has held it in 10 quarters since. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Winton Group held 52,398 shares of Arcus Biosciences worth $1.62M as of Q2 2026.
  • Winton Group bought 19,578 Arcus Biosciences shares in Q2 2026, an estimated $484K.
  • Arcus Biosciences made up 0.05% of Winton Group's portfolio in Q2 2026, its #360 holding.
  • Winton Group first reported a position in Arcus Biosciences in Q4 2021 and has held it in 10 quarters since.
  • 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.